Congress Park Capital’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $217K | Sell |
95,422
-578,264
| -86% | -$1.31M | 0.07% | 106 |
|
|
2025
Q1 | $428K | Sell |
673,686
-290,904
| -30% | -$185K | 0.16% | 84 |
|
|
2024
Q4 | $994K | Sell |
964,590
-251,418
| -21% | -$259K | 0.36% | 59 |
|
|
2024
Q3 | $1.43M | Buy |
1,216,008
+62,788
| +5% | +$74.1K | 0.53% | 44 |
|
|
2024
Q2 | $1.41M | Buy |
1,153,220
+919,420
| +393% | +$1.12M | 0.57% | 46 |
|
|
2024
Q1 | $510K | Sell |
233,800
-5,500
| -2% | -$12K | 0.23% | 78 |
|
|
2023
Q4 | $371K | Buy |
239,300
+126,850
| +113% | +$197K | 0.18% | 88 |
|
|
2023
Q3 | $145K | Buy |
112,450
+6,300
| +6% | +$8.13K | 0.08% | 111 |
|
|
2023
Q2 | $183K | Buy |
106,150
+5,950
| +6% | +$10.2K | 0.09% | 122 |
|
|
2023
Q1 | $151K | Buy |
+100,200
| New | +$151K | 0.08% | 125 |
|
|
2021
Q2 | – | Sell |
-20,207
| Closed | -$156K | – | 142 |
|
|
2021
Q1 | $156K | Sell |
20,207
-5,600
| -22% | -$43.2K | 0.09% | 125 |
|
|
2020
Q4 | $169K | Sell |
25,807
-52,754
| -67% | -$345K | 0.1% | 109 |
|
|
2020
Q3 | $522K | Sell |
78,561
-7,750
| -9% | -$51.5K | 0.32% | 57 |
|
|
2020
Q2 | $719K | Sell |
86,311
-12,300
| -12% | -$102K | 0.55% | 43 |
|
|
2020
Q1 | $756K | Buy |
98,611
+3,950
| +4% | +$30.3K | 0.68% | 35 |
|
|
2019
Q4 | $787K | Sell |
94,661
-73,150
| -44% | -$608K | 0.58% | 39 |
|
|
2019
Q3 | $1.24M | Sell |
167,811
-800
| -0.5% | -$5.9K | 1.04% | 28 |
|
|
2019
Q2 | $1.72M | Sell |
168,611
-42,895
| -20% | -$437K | 1.36% | 24 |
|
|
2019
Q1 | $2.27M | Buy |
211,506
+88,195
| +72% | +$948K | 1.97% | 16 |
|
|
2018
Q4 | $1.86M | Buy |
123,311
+11,125
| +10% | +$168K | 2.05% | 15 |
|
|
2018
Q3 | $2.08M | Buy |
112,186
+2,661
| +2% | +$49.2K | 1.86% | 15 |
|
|
2018
Q2 | $2.5M | Buy |
109,525
+1,800
| +2% | +$41.2K | 2.4% | 10 |
|
|
2018
Q1 | $3.07M | Sell |
107,725
-18,250
| -14% | -$519K | 3.15% | 6 |
|
|
2017
Q4 | $2.66M | Buy |
+125,975
| New | +$2.66M | 2.68% | 7 |
|